Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Dermata Therapeutics: Q2 Earnings Insights

  Dermata Therapeutics (NASDAQ:DRMA) reported its Q2 earnings results on Monday, August 15, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
byBenzinga Insights
August 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

 

Dermata Therapeutics (NASDAQ:DRMA) reported its Q2 earnings results on Monday, August 15, 2022 at 04:05 PM.

Here’s what investors need to know about the announcement.

Earnings

Dermata Therapeutics beat estimated earnings by 25.0%, reporting an EPS of $-0.24 versus an estimate of $-0.32.

Revenue was down $0 from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.07 which was followed by a 7.26% drop in the share price the next day.

 

Listen to the earnings announcement yourself by clicking here.

To track all earnings releases for Dermata Therapeutics visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Upstart Q1 Earnings: Revenue Beat, EPS Beat, Targeting Positive EBITDA In 2024 And More

By Adam Eckert
May 7, 4:27 PM
Upstart reported first-quarter revenue of $128 million, which beat the consensus estimate of $124.867 million, according to Benzinga Pro. Upstart's top-line results were up 24% year-over-year, but down 9% sequentially. The cloud-based AI lending platform company reported an adjusted loss of 31 cents per share, which beat analyst estimates for a loss of 39 cents per share.

UPST